173 related articles for article (PubMed ID: 16827120)
1. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
[TBL] [Abstract][Full Text] [Related]
2. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
[TBL] [Abstract][Full Text] [Related]
5. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
Das JR; Fryar EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
[TBL] [Abstract][Full Text] [Related]
7. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
[TBL] [Abstract][Full Text] [Related]
8. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
[TBL] [Abstract][Full Text] [Related]
10. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
11. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
[TBL] [Abstract][Full Text] [Related]
12. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
[TBL] [Abstract][Full Text] [Related]
13. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells.
Bowen D; Southerland WM; Hawkins M; Johnson DH
Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
15. Toxicity, pathological effects, and antineoplastic activity of a non-toxic dose of 5-fluorouracil in combination with methotrexate.
Robbins TJ; Bowen D
Anticancer Res; 1988; 8(1):43-9. PubMed ID: 3358639
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.
Tisman G; Wu SJ
Cancer Treat Rep; 1980; 64(8-9):829-35. PubMed ID: 7448820
[TBL] [Abstract][Full Text] [Related]
17. [Improving the anti-tumor activity of 5-fluorouracil by methotrexate].
Konishi T; Noie T; Abe T; Agawa S; Furushima K; Ito K; Mafune K; Makuuchi M; Teruya M; Nouchi T
Gan To Kagaku Ryoho; 1999 Mar; 26(4):431-9. PubMed ID: 10097739
[TBL] [Abstract][Full Text] [Related]
18. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Zhen YS; Taniki T; Weber G
Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584
[TBL] [Abstract][Full Text] [Related]
19. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.
Stuart EC; Rosengren RJ
Life Sci; 2008 Apr; 82(17-18):943-8. PubMed ID: 18371987
[TBL] [Abstract][Full Text] [Related]
20. [Biochemical modulation in cancer chemotherapy].
Kawasaki H; Nobori T; Kamiya H; Sakurai M
Gan To Kagaku Ryoho; 1985 Apr; 12(4):815-29. PubMed ID: 3985645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]